New pre-clinical data from ongoing studies supports further clinical evaluation of BNC101:Bionomics Ltd has recently released new pre-clinical data from ongoing studies of BNC101, cancer drug candidate being developed to treat solid cancer. The data presented at the annual American Association for Cancer Research conference in Washington, DC demonstrates complementary anti-tumor activity between BNC101 and checkpoint inhibitors (Checkpoint inhibitors seek to overcome one of cancer's main defenses against an immune system attack). The data strongly supports further clinical evaluation of BNC101 in combination with checkpoint inhibitors. Although a concrete outlook/ guidance on financials has not been provided for full year, BNO expects to continue with its investments in pipeline programs.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report Top Dividend Stocks to Consider in 2020CLICK HERE FOR YOUR FREE REPORT!